1. Home
  2. LYRA vs VRME Comparison

LYRA vs VRME Comparison

Compare LYRA & VRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • VRME
  • Stock Information
  • Founded
  • LYRA 2005
  • VRME 1999
  • Country
  • LYRA United States
  • VRME United States
  • Employees
  • LYRA N/A
  • VRME N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • VRME EDP Services
  • Sector
  • LYRA Health Care
  • VRME Technology
  • Exchange
  • LYRA Nasdaq
  • VRME Nasdaq
  • Market Cap
  • LYRA 18.0M
  • VRME 14.6M
  • IPO Year
  • LYRA 2020
  • VRME N/A
  • Fundamental
  • Price
  • LYRA $0.17
  • VRME $1.00
  • Analyst Decision
  • LYRA Buy
  • VRME Buy
  • Analyst Count
  • LYRA 5
  • VRME 1
  • Target Price
  • LYRA $4.50
  • VRME $1.50
  • AVG Volume (30 Days)
  • LYRA 2.2M
  • VRME 27.0K
  • Earning Date
  • LYRA 11-12-2024
  • VRME 11-12-2024
  • Dividend Yield
  • LYRA N/A
  • VRME N/A
  • EPS Growth
  • LYRA N/A
  • VRME N/A
  • EPS
  • LYRA N/A
  • VRME N/A
  • Revenue
  • LYRA $1,471,000.00
  • VRME $25,259,000.00
  • Revenue This Year
  • LYRA $13.99
  • VRME $1.14
  • Revenue Next Year
  • LYRA N/A
  • VRME $10.56
  • P/E Ratio
  • LYRA N/A
  • VRME N/A
  • Revenue Growth
  • LYRA 3.37
  • VRME N/A
  • 52 Week Low
  • LYRA $0.17
  • VRME $0.90
  • 52 Week High
  • LYRA $6.79
  • VRME $2.45
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 30.70
  • VRME 30.55
  • Support Level
  • LYRA $0.26
  • VRME $0.90
  • Resistance Level
  • LYRA $0.28
  • VRME $1.32
  • Average True Range (ATR)
  • LYRA 0.02
  • VRME 0.11
  • MACD
  • LYRA -0.01
  • VRME -0.03
  • Stochastic Oscillator
  • LYRA 1.69
  • VRME 20.92

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About VRME VerifyMe Inc.

VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.

Share on Social Networks: